<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two major classes of therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) have been described following the use of conventional doses of <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> and epipodophyllotoxins </plain></SENT>
<SENT sid="1" pm="."><plain>They are characterized by distinct clinical presentations and chromosomal abnormalities </plain></SENT>
<SENT sid="2" pm="."><plain>We report 2 cases of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 1 case of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in 3 out of 36 women who underwent high-dose chemotherapy and attempted ABMT for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Two patients developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> 4 and 8 months following the initiation of high-dose chemotherapy with or without ABMT </plain></SENT>
<SENT sid="4" pm="."><plain>The third patient developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> 23 months following dose-intensive chemotherapy and ABMT </plain></SENT>
<SENT sid="5" pm="."><plain>Cytogenetic studies of the marrow metaphase chromosomes from the two patients who developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, including FISH analysis in 1 patient, showed a t(9;11)(p22ng,q23) abnormal chromosome 6 (ring chromosome) </plain></SENT>
<SENT sid="6" pm="."><plain>Neither patient had a preleukemic phase </plain></SENT>
<SENT sid="7" pm="."><plain>Cytogenetic studies from the third patient who developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> showed abnormalities of chromosome 5 (-5) and a derivative of chromosome 17 </plain></SENT>
<SENT sid="8" pm="."><plain>The use of multiple chemotherapeutic agents in <z:hpo ids='HP_0000001'>all</z:hpo> 3 patients makes it difficult to attribute the development of these cases of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> to a single chemotherapeutic agent </plain></SENT>
<SENT sid="9" pm="."><plain>The possible role of dose-intensive chemotherapy in the development of these <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> is discussed </plain></SENT>
</text></document>